AUPH
Aurinia Pharmaceuticals Inc
$
11.430
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
11.670
Open
11.520
VWAP
11.49
Vol
3.33M
Mkt Cap
1.50B
Low
11.320
Amount
38.23M
EV/EBITDA(TTM)
14.56
Total Shares
143.02M
EV
1.29B
EV/OCF(TTM)
13.90
P/S(TTM)
6.43
Aurinia Pharmaceuticals Inc. is a fully integrated biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The Company is primarily engaged in the development of its pipeline asset AUR200, a differentiated, potential next generation therapy for autoimmune diseases that targets both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand). The Company contracted with Otsuka Pharmaceutical Co., Ltd. (Otsuka) as a collaboration partner for the development and commercialization of LUPKYNIS in the Otsuka Territories. It sells LUPKYNIS (voclosporin) primarily to specialty pharmacies and a specialty distributor and directly to its ex-U.S. partner, Otsuka.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
FY2026Q1
67.33M
-0.65%
--
--
69.93M
+16.81%
--
--
71.70M
+14.78%
--
--
Estimates Revision
The market is revising Upward the revenue expectations for Aurinia Pharmaceuticals Inc. (AUPH) for FY2025, with the revenue forecasts being adjusted by 0.13% over the past three months. During the same period, the stock price has changed by 40.94%.
Revenue Estimates for FY2025
Revise Upward
+0.13%
In Past 3 Month
Stock Price
Go Up
+40.94%
In Past 3 Month
4 Analyst Rating
-14.70% Downside
Wall Street analysts forecast AUPH stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for AUPH is 9.75 USD with a low forecast of 8.00 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
-14.70% Downside
Current: 11.430
Low
8.00
Averages
9.75
High
11.00
-14.70% Downside
Current: 11.430
Low
8.00
Averages
9.75
High
11.00
H.C. Wainwright
Arthur He
initiated
$17
2025-07-30
Reason
H.C. Wainwright
Arthur He
Price Target
$17
2025-07-30
initiated
Reason
H.C. Wainwright analyst Arthur He assumed coverage of Aurinia Pharmaceuticals with a Buy rating and $17 price target. Aurinia is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases, the analyst tells investors in a research note. The firm believes has a \"solid and sustainable\" foundation with its lupus nephritis franchise.
Cantor Fitzgerald
Olivia Brayer
Buy
Reiterates
$10
2024-09-16
Reason
Cantor Fitzgerald
Olivia Brayer
Price Target
$10
2024-09-16
Reiterates
Buy
Reason
Cantor Fitzgerald
Olivia Brayer
Buy
Reiterates
$10
2024-09-09
Reason
Cantor Fitzgerald
Olivia Brayer
Price Target
$10
2024-09-09
Reiterates
Buy
Reason
HC Wainwright & Co.
Ed Arce
Strong Buy
Reiterates
$13
2024-09-06
Reason
HC Wainwright & Co.
Ed Arce
Price Target
$13
2024-09-06
Reiterates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Aurinia Pharmaceuticals Inc (AUPH.O) is 18.19, compared to its 5-year average forward P/E of 0.42. For a more detailed relative valuation and DCF analysis to assess Aurinia Pharmaceuticals Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
0.42
Current PE
18.19
Overvalued PE
37.79
Undervalued PE
-36.94
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
1.82
Current EV/EBITDA
9.43
Overvalued EV/EBITDA
44.24
Undervalued EV/EBITDA
-40.60
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
14.02
Current PS
5.42
Overvalued PS
31.99
Undervalued PS
-3.96
Financials
Annual
Quarterly
FY2025Q2
YoY :
+22.41%
70.01M
Total Revenue
FY2025Q2
YoY :
-4679.82%
20.20M
Operating Profit
FY2025Q2
YoY :
+2879.64%
21.51M
Net Income after Tax
FY2025Q2
YoY :
+1500.00%
0.16
EPS - Diluted
FY2025Q2
YoY :
+180.11%
44.14M
Free Cash Flow
FY2025Q2
YoY :
+6.42%
89.84
Gross Profit Margin - %
FY2025Q2
YoY :
-4182.76%
35.52
FCF Margin - %
FY2025Q2
YoY :
+2338.89%
30.73
Net Margin - %
FY2025Q2
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
6.0M
USD
10
6-9
Months
0.0
USD
0
0-12
Months
82.6K
USD
2
Bought
0-3
3
13.6M
USD
Months
3-6
2
9.6M
USD
Months
6-9
4
14.0M
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
6.0M
USD
10
6-9
Months
0.0
USD
0
0-12
Months
82.6K
USD
2
Bought
0-3
3
13.6M
USD
Months
3-6
2
9.6M
USD
Months
6-9
4
14.0M
USD
Months
0-12
0
0.0
USD
Months
AUPH News & Events
Events Timeline
2025-07-31 (ET)
2025-07-31
06:10:01
Aurinia Pharmaceuticals reports Q2 EPS 16c, consensus 15c
2025-06-30 (ET)
2025-06-30
06:02:26
Aurinia Pharma reports 'positive' results from Phase 1 study of aritinercept
2025-05-22 (ET)
2025-05-22
06:10:37
Aurinia Pharmaceuticals' Lupkinis therapy shows efficacy in lupus nephritis
Sign Up For More Events
Sign Up For More Events
News
4.0
08-05NASDAQ.COMAurinia Pharmaceuticals Reaches Analyst Target Price
7.0
07-31SeekingAlphaAurinia raises 2025 revenue outlook to $270M as LUPKYNIS accelerates market penetration
9.5
07-31NewsfilterAurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2025
Sign Up For More News
People Also Watch
COHU
Cohu Inc
19.550
USD
+3.71%
UP
Wheels Up Experience Inc
1.370
USD
0.00%
WOOF
Petco Health and Wellness Company Inc
3.130
USD
+4.33%
CARS
Cars.com Inc
11.770
USD
-10.36%
GETY
Getty Images Holdings Inc
1.780
USD
-3.78%
WEAV
Weave Communications Inc
7.750
USD
+4.31%
EFC
Ellington Financial Inc
12.660
USD
-0.47%
BBSI
Barrett Business Services Inc
46.870
USD
+5.59%
VSAT
Viasat Inc
26.220
USD
-5.75%
NX
Quanex Building Products Corp
19.690
USD
+2.82%
FAQ
What is Aurinia Pharmaceuticals Inc (AUPH) stock price today?
The current price of AUPH is 11.43 USD — it has decreased -1.55 % in the last trading day.
What is Aurinia Pharmaceuticals Inc (AUPH)'s business?
What is the price predicton of AUPH Stock?
What is Aurinia Pharmaceuticals Inc (AUPH)'s revenue for the last quarter?
What is Aurinia Pharmaceuticals Inc (AUPH)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Aurinia Pharmaceuticals Inc (AUPH)'s fundamentals?
How many employees does Aurinia Pharmaceuticals Inc (AUPH). have?